Jacques Servier, the founder of France's second-largest pharmaceutical group who became ensnared...
The company that owns an Evansville, Indiana printing plant says it will be shutting it down in...
Novartis Pharma K.K. said Thursday its president Yoshiyasu Ninomiya and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.
Impax Laboratories today announced that Jeffrey D. Nornhold has been appointed Senior Vice President, Technical Operations and will oversee the Company's manufacturing, supply chain, quality and technical operations. Mr. Nornhold previously served as the Company's Senior Vice President, Global Quality Affairs since March 2011.
Par Pharmaceutical Companies today announced that Terrance J. Coughlin has been named chief operating officer. In this capacity, Mr. Coughlin will be responsible for Par's global manufacturing activities, research and development efforts and will be instrumental in the new product selection process.
Tris Pharma has announced several key management changes, including the new appointment of Mr. Stephen J. Kovary to the position of Vice President of Operations.
OsoBio has appointed Catherine R. Buck director of manufacturing. In her capacity, Buck is responsible for ensuring that OsoBio’s operations comply with current Good Manufacturing Practices (cGMP) as they apply to the manufacturing of injectable sterile liquid, suspension and lyophilized pharmaceutical products.
Merck has announced the appointment of Robert M. Davis, 47, as executive vice president and chief financial officer, effective April 23, 2014. Davis, who will also oversee corporate strategy and corporate business development, will succeed Peter N. Kellogg, 58.
Quintiles has announced that Stella Blackburn, M.B. B.S., has been appointed as the vice president and global head of Risk Management for its Real-World & Late Phase Research group. In this role, Dr. Blackburn will be responsible for leading the group’s risk management efforts in North America, EU and Asia-Pacific.
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced that the company’s Board of Directors has appointed Paul L. Berns, Anacor’s Chairman of the Board of Directors, to assume the role of President and Chief Executive Officer, effective immediately.
Chembio Diagnostics, Inc. a company that provides point-of-care ("POC") diagnostic tests for infectious diseases, today announced the appointment of John Sperzel as President and CEO, effective March 13, 2014.
Avion Pharmaceuticals, a specialty pharmaceutical company, recently announced the promotion of Mike Sullivan to the position of President.
Harvard Bioscience, a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, has named Ronald Aplin to Vice President Global Operations and Quality, effective immediately.
Eisai Inc. has announced the appointments of Yuji Matsue as chairman and chief executive officer and Shaji Procida as president and chief operating officer, effective April 1, 2014. Mr. Matsue and Ms. Procida succeed current President and CEO Lonnel Coats, who will be retiring from Eisai in June 2014 after 18 years.
Avantor Performance Materials, a global manufacturer and supplier of high-performance chemistries, announces the appointment of Richard Gaynor as chief financial officer.
Endo International has appointed Susan Hall, Ph.D. as executive vice president, chief scientific officer and global head of research & development and quality, effective March 10, 2014.
Roche announced today that William Pao, M.D., Ph.D., Professor of Medicine and Head of the Hematology-Oncology Division at Vanderbilt University Medical Center in the US, will join Roche Pharma Research and Early Development (pRED) as Global Head of the Oncology Disease and Translational Area.
Horizon Pharma today announced the appointment of Robert F. Carey as executive vice president and chief business officer, bringing a broad base of healthcare investment banking experience.
Hospira today announced that David J. Endicott has been named President, Hospira Medical Devices, effective March 10, 2014. In this newly created role, Mr. Endicott will have responsibility for establishing a fully integrated device organization.
First the teenager survived a rare cancer. Then she wanted to study it, spurring a study that helped scientists find a weird gene flaw that might play a role in how the tumor strikes.
Andrew Sandford joins Catalent as Vice President Business Development, Biologics, and will focus on growth of the company’s existing biologics offerings and, Dr. Jennifer Mitcham jas been appointed Director, Business Development for Antibody-Drug Conjugates (ADC), Biologics.
Jazz Pharmaceuticals has announced that Kathryn Falberg, executive vice president and chief financial officer (CFO), has resigned from the company, effective March 9, 2014, to pursue other interests. Falberg will serve as a consultant to Jazz Pharmaceuticals during a transition period.
Pharmaceutical Product Development, LLC (PPD) has appointed Patrick Bennett as executive director of laboratory operations for a new biomarker services division of its bioanalytical laboratory.
OsoBio has appointed Paul W. Stoker, Ph.D., director of its chemistry and microbiology laboratories. Stoker fills a position vacated when Kathleen Larese, OsoBio’s previous director of laboratories, became the company’s director of technical operations.
Jean-Christophe Tellier, currently UCB’s Executive Vice President, Biopharma Brands and Solutions, will be appointed Chief Executive Officer-Elect and Chairman of the Executive Committee as of March 1, 2014. Jean-Christophe Tellier will also be proposed to be appointed as a member of the Board of Directors at the next Annual General Meeting of Shareholders on April 24, 2014.
EMD Serono, Inc. announced today the recent appointments of Gary Zieziula as the company’s Chief Commercial Officer, Allene Diaz as Senior Vice President of Managed Markets, Lisa Buffington as Vice President of US Communications, Alexander Kuta as Vice President and Head of US Regulatory Affairs, and Michael Ruggiero as Vice President of US Government Affairs and Policy.
Actavis plc has announced a realignment of its global strategic business structure to maximize the company's position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth.
- Page 1